The mammalian target of rapamycin (mTOR) inhibitor—everolimus—and the CDK4/6 inhibitors—palbociclib and ribociclib—have been approved to treat breast cancer patients who are HER2-negative and hormone receptor (HR)-positive [36,37,38,39,40]. Here, MTOR is linked to breast carcinoma.